CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the role of epigenetic changes in chemotherapy resistance in triple-negative breast cancer. By analyzing chromatin states and their transmission, it aims to understand how these changes contribute to drug resistance and to develop new therapeutic strategies.
The emergence of resistance to chemotherapy and targeted therapies is a major challenge for the treatment of cancer.
While several genetic mechanisms driving resistance processes have been discovered, non-genetic mechanisms have also been shown to contribute to drug resistance.
Yet, our restricted understanding of epigenetic evolution has so far limited our ability to modulate resistance using epigenetic modifiers.
With ChromTrace, our goal is to reconstruct and define the contribution of epigen…
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Paris
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
